INDV

Peers: ALKS AMRX EBS SUPN COLL NBIX PCRX AQST ACAD HRMY

Index	-
Market Cap	5.85B
Enterprise Value	6.04B
Income	450.00M
Sales	1.37B
Book/sh	-0.51
Cash/sh	1.47
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	Nov 03, 2026
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	838
IPO	Dec 29, 2014

P/E	7.79
Forward P/E	6.70
PEG	0.29
P/S	4.26
P/B	-
P/C	19.17
P/FCF	225.25
EV/EBITDA	9.55
EV/Sales	4.40
Quick Ratio	0.50
Current Ratio	0.62
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / No

EPS (ttm)	3.61
EPS next Y	4.20
EPS next Q	0.99
EPS this Y	57.53%
EPS next Y	6.74%
EPS next 5Y	23.16%
EPS past 3/5Y	- -
Sales past 3/5Y	11.20% 13.88%
EPS Y/Y TTM	265.06%
Sales Y/Y TTM	16.44%
EPS Q/Q	244.87%
Sales Q/Q	13.38%
Earnings	Oct 29 BMO
EPS/Sales Surpr.	24.45% 8.09%

Insider Own	3.00%
Insider Trans	-1.51%
Inst Own	97.31%
Inst Trans	-8.86%
ROA	32.75%
ROE	-
ROIC	-
Gross Margin	85.08%
Oper. Margin	45.05%
Profit Margin	32.75%
SMA20	3.78%
SMA50	3.11%
SMA200	1.68%
Trades

Shs Outstand	124.77M
Shs Float	121.03M
Short Float	7.78%
Short Ratio	2.94
Short Interest	9.41M
52W High	33.22 -15.25%
52W Low	21.48 31.07%
Volatility	4.60% 3.65%
ATR (14)	0.98
RSI (14)	58.42
Beta	1.13
Rel Volume	0.00
Avg Volume	3.21M
Volume	0

Perf Week	4.49%
Perf Month	0.81%
Perf Quarter	-6.33%
Perf Half Y	-8.36%
Perf YTD	1.11%
Perf Year	23.53%
Perf 3Y	82.86%
Perf 5Y	115.31%
Perf 10Y	66.04%
Recom	1.33
Target Price	48.67
Prev Close	28.15
Price	28.15
Change %	0.00%

Consensus

Strong Buy

Avg. Price Target

$48.67

Implied Upside

+72.9%

Analysts7incl. previous ratings

Rating Distribution7 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Jun 18, 2026	Initiated	BBarclays	Overweight	$46	+63.4%
Aug 06, 2025	Initiated	HH.C. Wainwright	Buy	$27	-4.1%
Jul 22, 2025	Resumed	JJefferies	Buy	$20	-29.0%
Jan 28, 2025	Initiated	RRodman & Renshaw	Buy	$16	-43.2%
Jul 23, 2024	Initiated	PPiper Sandler	Overweight	$22	-21.8%
Apr 03, 2024	Initiated	CCraig Hallum	Buy	$37	+31.4%
Jul 13, 2023	Initiated	NNorthland Capital	Outperform	$35	+24.3%

Oct-29-26 07:00AM	Indivior Reports Third Quarter 2026 Financial Results (GlobeNewswire)
Oct-28-26 05:43PM	Updated Effective Date: Huron Consulting Group Set to Join S&P SmallCap 600 (PR Newswire)
Oct-22-26 06:08PM	MSG Rangers and Huron Consulting Group Set to Join S&P SmallCap 600 (PR Newswire)
Oct-21-26 01:03PM	Indivior Heads Into Q3 With Street Estimates Trailing Its Raised Revenue Outlook (Earnings Whispers)
Oct-19-26 08:30AM	Indivior to Report Third Quarter 2026 Financial Results (GlobeNewswire)
01:53PM	Loading…
Sep-29-26 01:53PM	Are LFCR, ITGR, FHB, INDV Obtaining Fair Deals for their Shareholders? (PR Newswire)
Sep-17-26 07:00AM	Indivior Pharmaceuticals, Inc. Declares Special Cash Dividend (GlobeNewswire)
Aug-03-26 08:47AM	Indivior Shares Surge After Strong Quarterly Results and Higher 2026 Outlook (InvestorsHub) -6.60%
08:28AM	Supernus Shares Jump After Revenue Beat, Higher Guidance and Indivior Merger Announcement (InvestorsHub)
08:22AM	Supernus jumps premarket on merger deal; GameStop drops (Investing.com)
06:31AM	Indivior Reports Second Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance (GlobeNewswire)
Jul-31-26 12:44PM	This Pharma Stock Eyes Entry As Opioid Addiction Specialist's Profits Surge 108% (Investor's Business Daily)
Jul-23-26 10:00AM	Indivior to Report Second Quarter 2026 Financial Results and Host Webcast (GlobeNewswire)
Jun-25-26 11:27AM	IBD 50 Stock Indivior Breaks Out Amid Big Fund Ownership Expansion, Strong Profit Prospects (Investor's Business Daily)
May-20-26 09:00AM	New Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare Utilization (GlobeNewswire)
07:00AM	Loading…
May-14-26 07:00AM	Indivior to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-12-26 01:38PM	Medical Stock In Buy Zone After Breakout By Opioid-Addiction Treatment Maker (Investor's Business Daily)
May-04-26 07:00AM	Indivior Announces $175 Million Accelerated Share Repurchase (GlobeNewswire)
Apr-30-26 07:00AM	Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance (GlobeNewswire) +7.70%
Apr-24-26 11:00AM	Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder (GlobeNewswire)
Apr-16-26 02:30PM	Survey of Correctional Facility Staff: Monthly Opioid Treatment Shot May Help Reduce Medication Misuse (GlobeNewswire)
Apr-09-26 07:00AM	Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th (GlobeNewswire)
Mar-31-26 09:00AM	New Cost Impact Model Highlights Potential for Monthly Injectable Buprenorphine to Reduce Staffing Burdens in Correctional Facilities (GlobeNewswire) +5.91%
Mar-17-26 12:02PM	National Survey Finds Only 58% of U.S. Correctional Facilities Offer Medications for Opioid Use Disorder (GlobeNewswire)
Mar-12-26 08:30PM	Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering (GlobeNewswire) -6.00%
07:00AM	Indivior Announces Proposed Convertible Senior Notes Offering (GlobeNewswire)
Mar-11-26 09:00AM	New Study Shows Adherence to Monthly Injectable Buprenorphine Linked to Lower Healthcare Utilization and Costs in Opioid Use Disorder (GlobeNewswire)
Mar-09-26 12:35PM	Implied Volatility Surging for Indivior Pharmaceuticals Stock Options (Zacks)
Feb-26-26 09:55AM	Indivior Pharmaceuticals Inc. (INDV) Tops Q4 Earnings and Revenue Estimates (Zacks)
09:16AM	Indivior Q4 Earnings Call Highlights (MarketBeat)
07:00AM	Loading…
07:00AM	Indivior Reports Fourth Quarter and Full-Year 2025 Financial Results (GlobeNewswire)
Feb-24-26 07:00AM	Indivior to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-19-26 09:45AM	Indivior Pharmaceuticals to Report Q4 Earnings: What's in the Cards? (Zacks)
Jan-28-26 07:00AM	Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26?? (GlobeNewswire)
Jan-26-26 07:00AM	Indivior Announces Completion of Redomiciliation to the United States (GlobeNewswire)
Jan-21-26 07:17AM	Strength Seen in Ardelyx (ARDX): Can Its 15.0% Jump Turn into More Strength? (Zacks)
04:54AM	'Follow The Money,' Not The Tariff Noise, Says Expert, Spotlights This New S&P Data Center Cooling Stock Among Top Picks (Benzinga)
Jan-13-26 09:19AM	Sanofi's Teizeild Gets EU Approval for Treating Type 1 Diabetes (Zacks)
Jan-12-26 10:14AM	PCRX Stock Down 10% as Preliminary Q4 Revenues Miss Estimates (Zacks)
10:08AM	TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug (Zacks)
08:43AM	Take the Zacks Approach to Beat the Markets: Indivior, FIGS & Ulta Beauty in Focus (Zacks)
Jan-10-26 02:57PM	Indivior PLC (INDV) Announces Full-Year 2026 Financial Guidance (Insider Monkey)
Jan-09-26 11:46AM	AMRN Stock Up 17% as Preliminary Q4 Sales Beat Expectations (Zacks)
Jan-08-26 11:09AM	GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug (Zacks)
08:57AM	4 Stocks Trading Near 52-Week High With Room to Rise Further (Zacks)
07:00AM	Indivior Provides Full-Year 2026 Financial Guidance and Business Update (GlobeNewswire)
Jan-07-26 11:45AM	FDA Grants Breakthrough Therapy Designation to ALKS' Narcolepsy Drug (Zacks)
09:53AM	OTLK Stock Crashes 67% in a Week: Here's What You Need to Know (Zacks)
Jan-06-26 11:53AM	ALT Stock Up 17% After Pemvidutide Gets FDA Breakthrough Tag for MASH (Zacks)
Dec-30-25 10:32AM	Why This Top 100 Stock to Buy Is Getting Cheaper Even as It Soars Higher (Barchart)
Dec-22-25 07:00AM	Indivior Announces Inclusion in the S&P SmallCap 600 Index (PR Newswire)
06:00AM	2026 outlook: Small-cap biotechs may fill gaps on drug pipelines (Yahoo Finance Video)
Dec-17-25 11:30AM	New Study Shows Extended-Release Buprenorphine Safely Delivers Rapid, Clinically Meaningful Reductions in Opioid Use and Supports Abstinence in High-Risk Populations (PR Newswire)
Dec-05-25 05:49PM	CRH, Carvana and Comfort Systems USA Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 (PR Newswire)
Nov-20-25 04:01PM	Indivior Concludes Legacy U.S. Department of Justice Matter (PR Newswire)
Nov-19-25 09:21AM	Indivior to Participate in the Piper Sandler 37th Annual Healthcare Conference (PR Newswire)
Nov-07-25 08:37AM	4 Must-Buy Efficient Stocks to Enrich Your Portfolio in 2025 (Zacks)
Nov-06-25 03:25PM	3 Top Ranked Stocks that are the Best of the Best (Zacks)
Nov-03-25 08:00AM	Indivior Presents New Real-World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine (PR Newswire) +6.23%
Oct-31-25 10:03AM	Indivior (INDV) Jumps to New High on Earnings Blowout, Optimistic Outlook (Insider Monkey)
Oct-30-25 04:22PM	Indivior PLC (INDV) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com) +15.41%
02:18PM	Here's Why Indivior Stock Soared 15% Today (Motley Fool)
08:30AM	Indivior PLC (INDV) Beats Q3 Earnings and Revenue Estimates (Zacks)
07:00AM	Indivior Reports Third Quarter 2025 Financial Results and Raises Full-Year 2025 Financial Guidance (PR Newswire)
Oct-29-25 09:40AM	Indivior PLC (INDV) Q3 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Oct-28-25 10:00AM	Indivior to Participate in the Stifel 2025 Healthcare Conference (PR Newswire)
Oct-23-25 09:21AM	Indivior PLC (INDV) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-16-25 04:04PM	Indivior to Report Third Quarter 2025 Financial Results and Host Webcast on October 30th (PR Newswire)
Oct-15-25 08:00AM	Clinical Evidence Supports Rapid SUBLOCADE Induction as a Strategy to Improve Retention in Opioid Use Disorder Treatment (PR Newswire)
Oct-01-25 08:00AM	Indivior Proposes New Corporate Structure to Achieve U.S. Domiciliation (PR Newswire)
Sep-30-25 12:47PM	Indivior PLC (INDV) Raises 2025 Guidance After Q2 Revenue Hits $302M (Insider Monkey)
Sep-10-25 12:00PM	What Makes Indivior PLC (INDV) a Strong Momentum Stock: Buy Now? (Zacks)
Sep-09-25 11:57AM	Top 100 Stocks to Buy: Indivior Advances Into Top 50 on Momentum (Barchart)
Aug-20-25 12:00PM	Indivior to Participate in Upcoming Investor Events (PR Newswire)
Aug-06-25 09:36AM	Snap downgraded, Leidos upgraded: Wall Street's top analyst calls (The Fly)
Aug-05-25 12:00PM	All You Need to Know About Indivior (INDV) Rating Upgrade to Strong Buy (Zacks)
10:00AM	Best Momentum Stock to Buy for August 5th (Zacks)
06:16AM	New Strong Buy Stocks for August 5th (Zacks)
Aug-03-25 12:32PM	Indivior Plc (INDV) Jumps 22.8% on Impressive Earnings, Outlook (Insider Monkey)
Aug-01-25 01:23PM	Indivior (INDV) Extends Jump on 3rd Day with 16% Gain (Insider Monkey)
Jul-31-25 08:15AM	Indivior PLC (INDV) Tops Q2 Earnings and Revenue Estimates (Zacks) +16.09%
07:00AM	Indivior Reports Second Quarter 2025 Financial Results and Raises FY 2025 Financial Guidance (PR Newswire)
Jul-30-25 09:43AM	Indivior PLC (INDV) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Jul-28-25 10:06AM	Indivior PLC (INDV) Reinvents Leadership, Moves Listing to Nasdaq (Insider Monkey)
10:00AM	BioCryst Pharmaceuticals (BCRX) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Jul-25-25 02:00AM	Indivior Announces Completion of Cancellation of Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained (PR Newswire)
Jul-24-25 10:00AM	Indivior PLC (INDV) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-23-25 08:00AM	Indivior Real World Evidence Study Finds Medications for Opioid Use Disorder, Particularly Extended-Release Buprenorphine, Reduced Odds of Emergency Department Visits for Patients with Opioid Use Disorder (PR Newswire)
Jul-17-25 09:00AM	Indivior to Report Second Quarter 2025 Financial Results and Host Webcast on July 31st (PR Newswire)
Jul-08-25 08:00AM	Indivior Appoints Vanessa Procter as Executive Vice President of Corporate Affairs (PR Newswire)
Jul-01-25 07:05AM	Indivior (INDV) Moves 5.7% Higher: Will This Strength Last? (Zacks)
Jun-30-25 07:00AM	Indivior Announces Inclusion in the U.S. Russell 2000 and 3000 Indexes (PR Newswire) +5.66%
Jun-27-25 05:45PM	IGC Pharma, Inc. (IGC) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
Jun-24-25 04:12PM	Indivior Appoints Tony Kingsley to the Board of Directors (PR Newswire)
02:07PM	Teladoc (TDOC) Moves 14.4% Higher: Will This Strength Last? (Zacks)
10:40AM	Strength Seen in Nektar (NKTR): Can Its 12.1% Jump Turn into More Strength? (Zacks)
07:56AM	RGC Resources (RGCO) Surges 9.1%: Is This an Indication of Further Gains? (Zacks)
Jun-20-25 03:01AM	Addex Therapeutics Ltd (ADXN) Q1 2025 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
Jun-19-25 09:00AM	Indivior Presents New Data at CPDD Demonstrating that High Buprenorphine Exposure May Improve Treatment Outcomes in High Fentanyl Users (PR Newswire)
Jun-05-25 05:08AM	Wise Plans to Shift Main Listing to US in Latest London Loss (Bloomberg)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Anderson Woodrow D	Chief Accounting Officer	Aug 27 '26	Buy	35.69	1,500	53,535	27,638	Aug 27 04:00 PM
Anderson Woodrow D	Chief Accounting Officer	Aug 05 '26	Buy	36.28	1,500	54,420	26,138	Aug 05 04:52 PM
Heidbreder Christian	Chief Scientific Officer	Jul 10 '26	Sale	41.14	18,586	764,628	209,337	Jul 13 04:31 PM
Heidbreder Christian	Officer	Jul 10 '26	Proposed Sale	41.14	18,586	764,628		Jul 10 10:01 AM
Heidbreder Christian	Chief Scientific Officer	Jun 11 '26	Sale	38.06	18,586	707,383	227,923	Jun 12 04:10 PM
Heidbreder Christian	Officer	Jun 11 '26	Proposed Sale	38.06	18,586	707,383		Jun 11 11:20 AM
Preblick Ryan	Chief Financial Officer	Jun 08 '26	Sale	37.70	36,000	1,357,200	284,751	Jun 10 06:04 AM
Preblick Ryan	Officer	Jun 08 '26	Proposed Sale	37.70	36,000	1,357,200		Jun 08 01:58 PM
Ryan Barbara	Director	Mar 13 '26	Buy	31.09	8	249	5,724	Mar 13 04:25 PM
Kingsley Stuart A	Director	Mar 06 '26	Buy	31.86	940	29,953	5,582	Mar 11 09:54 AM
Ryan Barbara	Director	Mar 09 '26	Buy	32.56	31	1,009	5,716	Mar 11 08:12 AM
Ryan Barbara	Director	Jan 05 '26	Buy	35.39	775	27,429	1,963	Jan 07 01:51 PM
Humphreys Keith	Director	Jan 05 '26	Buy	35.39	775	27,429	5,802	Jan 07 01:50 PM
NINIVAGGI DANIEL A	Director	Jan 05 '26	Buy	35.39	775	27,429	16,923	Jan 07 01:49 PM
Stejbach Mark	Director	Jan 05 '26	Buy	35.39	775	27,429	16,847	Jan 07 01:48 PM
Wheadon David E.	Director	Jan 05 '26	Buy	35.39	1,771	62,680	14,395	Jan 07 01:47 PM
Cetani Cynthia C	Officer	Nov 07 '25	Proposed Sale	30.65	121,737	3,731,762		Nov 07 04:05 PM

Indivior Pharmaceuticals, Inc. is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company was founded on December 23, 2014 and is headquartered in North Chesterfield, VA.

CEO & DirectorMr. Joseph J. Ciaffoni

Chief Financial OfficerMr. Ryan Preblick

Chief Scientific OfficerDr. Christian Heidbreder

Chief Legal OfficerMr. Jeffrey W. Burris J.D.

Chief Commercial OfficerMr. Patrick a. Barry

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Indivior Pharmaceuticals Inc

Upgrade your Finviz experience